Recent clinical trials have shown that anti-PD-L1/PD-1 antibodies produced both durable tumor regression and prolonged disease stabilization in patients with non-small-cell lung cancer[7], melanoma[6], renal-cell cancer[8], and pancreatic cancer[9]. The gene discussed is CD274; the disease is renal cell adenocarcinoma.